Previous trials have demonstrated a close link between COVID-19 disease severity and elevated IL-6 levels; however, most IL-6 neutralizing agents, such as tocilizumab, have shown modest benefit in patients hospitalized with COVID-19 [10, 11]. Here, IL6 is linked to COVID-19.